DK1076566T3 - Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet - Google Patents

Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet

Info

Publication number
DK1076566T3
DK1076566T3 DK99919755T DK99919755T DK1076566T3 DK 1076566 T3 DK1076566 T3 DK 1076566T3 DK 99919755 T DK99919755 T DK 99919755T DK 99919755 T DK99919755 T DK 99919755T DK 1076566 T3 DK1076566 T3 DK 1076566T3
Authority
DK
Denmark
Prior art keywords
antigen
express
constructively
attenuated salmonella
salmonella mutants
Prior art date
Application number
DK99919755T
Other languages
English (en)
Inventor
Marcelo Sztein
Myron M Levine
Fernando R Noriega
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK1076566T3 publication Critical patent/DK1076566T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99919755T 1998-05-13 1999-04-30 Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet DK1076566T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen

Publications (1)

Publication Number Publication Date
DK1076566T3 true DK1076566T3 (da) 2006-11-13

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99919755T DK1076566T3 (da) 1998-05-13 1999-04-30 Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet

Country Status (16)

Country Link
US (1) US6190669B1 (da)
EP (1) EP1076566B1 (da)
JP (1) JP4363782B2 (da)
AT (1) ATE333285T1 (da)
AU (1) AU754795B2 (da)
CA (1) CA2328056C (da)
DE (1) DE69932425T2 (da)
DK (1) DK1076566T3 (da)
ES (1) ES2268864T3 (da)
HU (1) HUP0101747A3 (da)
MX (1) MXPA00011075A (da)
NO (1) NO20005672L (da)
NZ (1) NZ508110A (da)
PL (1) PL192378B1 (da)
WO (1) WO1999058146A1 (da)
ZA (1) ZA200006381B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141427C (en) * 1992-07-31 2008-07-22 Mohammed Anjam Khan Expression of recombinant fusion proteins in attenuated bacteria
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
DK1112747T3 (da) * 1999-12-28 2004-10-25 Akzo Nobel Nv Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
EP1280912B1 (en) * 2000-04-20 2006-12-27 University of Maryland, Baltimore Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) * 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
AU2003250250B2 (en) * 2002-06-19 2008-02-14 Intrexon Actobiotics Nv Methods and means to promote gut absorption
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
AU2006308966A1 (en) * 2005-10-28 2007-05-10 University Of Maryland, Baltimore Attenuated salmonella enterica Serovar Paratyphi A and uses thereof
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
RU2420569C2 (ru) 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
JP2009531029A (ja) * 2006-03-20 2009-09-03 ヴリジェ ユニヴェルシテ ブリュッセル 弱毒化サルモネラ生ワクチン
EP2004802A1 (en) * 2006-03-20 2008-12-24 Vrije Universiteit Brussel Live attenuated salmonella vaccine
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
JP2011502165A (ja) * 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
ES2599905T3 (es) * 2007-11-01 2017-02-06 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para aumentar las respuestas inmunitarias a Eimeria
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
HUE037157T2 (hu) 2010-01-21 2018-08-28 Univ Arkansas Vakcinavektorok, és eljárások immunválaszok fokozására
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
PL2956165T3 (pl) 2013-02-14 2020-04-30 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi immunologicznych na Eimeria lub ograniczania infekcji Eimeria
EP3578190A1 (en) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
IL311368A (en) * 2021-09-10 2024-05-01 Univ Minnesota Salmonella engineered for non-toxic colonization of crops

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
CA2328056A1 (en) 1999-11-18
MXPA00011075A (es) 2002-04-24
ES2268864T3 (es) 2007-03-16
DE69932425D1 (de) 2006-08-31
NO20005672D0 (no) 2000-11-10
EP1076566B1 (en) 2006-07-19
EP1076566A1 (en) 2001-02-21
US6190669B1 (en) 2001-02-20
WO1999058146A1 (en) 1999-11-18
ATE333285T1 (de) 2006-08-15
EP1076566A4 (en) 2005-01-05
HUP0101747A2 (hu) 2001-09-28
DE69932425T2 (de) 2007-03-08
JP4363782B2 (ja) 2009-11-11
HUP0101747A3 (en) 2002-03-28
AU754795B2 (en) 2002-11-28
NZ508110A (en) 2002-10-25
PL344593A1 (en) 2001-11-05
AU3740599A (en) 1999-11-29
NO20005672L (no) 2001-01-15
JP2002514398A (ja) 2002-05-21
ZA200006381B (en) 2002-02-07
CA2328056C (en) 2010-07-06
PL192378B1 (pl) 2006-10-31

Similar Documents

Publication Publication Date Title
DK1076566T3 (da) Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet
DK142391A (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DE69841437D1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
BR9916132A (pt) Composições e utilização das mesmas
FI913215A (fi) Additionspolymeriseringskatalysator, som aktiveras medelst oxidering.
MX9102664A (es) Composiciones termofijas de recubrimiento que tienen dureza mejorada.
DE69103489T2 (de) Filmbildende Organopolysiloxanzusammensetzung.
DE69113509T2 (de) Gasdetektor.
FR2661183B1 (fr) Compositions stabilisees de polymere halogene.
FR2661182B1 (fr) Compositions stabilisees de polymere halogene.
DE69106925D1 (de) Härtbare fluoreszierende Siloxanzusammensetzungen.
ATE386049T1 (de) Epstein-barr virus type b ctl epitopen
DE69102205D1 (de) Oberflächenaktive Polyorganosiloxane.
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
FI920080A0 (fi) Kulfaongare, som uppstannar kulor.
IT8123022A0 (it) Frigorifero, congelatore o simile, elettrodomestico, in particolare perfezionato.
FI911258A (fi) Foer kylmaskin, i synnerhet foer hushaollskylskaop avsedd plaotkondensator.
TR199600082A2 (tr) Gelistirilmis üstüne yazma özelliklerine sahip, ozona zarar vermeyen düzeltme yapma sivisi.
AU3487799A (en) Improved live attenuated viruses for use as vectors or vaccines
GB2021391A (en) Furniture composed of modular elements of U-shaped cross-section
KR960006037U (ko) 문자·그림등의 표기기구
IT8223644A0 (it) Serracavo, particolarmente per elettrodomestici o simili.
Hollander Above the Glass Ceiling